| Ytd | -56.14% | |
| 1y | -89.31% |
| Open | 4.08 | Prev Close | 4.02 | Low | 4.01 | High | 4.16 | Mkt Cap | 9.04M |
| Vol | 3.62K | Avg Vol | 48.03K | EPS | 1486.87 | P/E | N/A | Forward P/E | -0.83 |
| Beta | 5.07 | Short Ratio | 0.47 | Inst. Own | 11.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.51 | 200-d Avg | 9.67 | 1yr Est | 21.00 |
APVO News
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel mult
Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-base
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's
Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-mark
https://patentcenter.uspto.gov/applications/17634631/ifw/docshttps://x.com/PatentGrants/status/20749
SEATTLE, WA / ACCESS Newswire / June 30, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-s
Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new ra
https://patentcenter.uspto.gov/applications/16871597/ifw/docshttps://x.com/PatentGrants/status/20597
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel mult
50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs Innovation and I
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism a
Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, w
The Company is on track to complete the Phase 1b dose-optimization trial and select the recommended
Program Enters Final Stage of Dose Optimization Data Continue to Demonstrate Strong Clinical Activit
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism a
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(6.23) per share which beat the anal
Latest mipletamig data delivers 86% clinical benefit rate with no cytokine release syndrome in 28 fr
SEATTLE, WA / ACCESS Newswire / March 19, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the recipient of a significant decline
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy al
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy al
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the recipient of a large decrease in s
Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immu
Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as th
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the recipient of a large decline in sh
Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029,
Shares of Aptevo Therapeutics Inc. (NASDAQ: APVO) are trading lower Friday after the Seattle-based c
Shares of Aptevo Therapeutics are trading lower Friday after the Seattle-based company announced a o
SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinic
Neumora Therapeutics (NASDAQ: NMRA - Get Free Report) and Aptevo Therapeutics (NASDAQ: APVO - Get Fr
100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design un
100% of patients in Cohorts 1-3 remain free of cytokine release syndrome CRIS-7-derived CD3 design u
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(2.23) per share which missed the an
